The investigation revealed considerable similarities between SOCS1 and several immune checkpoints such as CTLA4, demonstrating SOCS1’s role as an independent prognostic factor positively influencing glioma patient outcomes. This evidence concerns the gene CTLA4 and central nervous system cancer.